Addictions and Their Treatment Recorded Summer Webinar CME Series

This enduring material expires on September 1, 2015.

Agenda

  Go
  •  
    Saturday, September 1, 2012

    (Tuesday, September 1, 2015)
    General Concepts - Webinar Recorded from July 9, 2012

    Kevin Sevarino, MD, PhD
    Yale University School of Medicine
    Connecticut VA Healthcare System
    Newington, Connecticut

    Release Date: September 1, 2012 Expiration Date: September 1, 2015

    Educational Objectives
    At the conclusion of this enduring material, participants should be able to:
    Define addiction or substance dependence.
    Examine epidemiology and impact of the addiction disorders.
    Review treatment concepts. 

    Faculty Disclosure
    AAAP and the Brown CME Program aim to provide educational information that is balanced, independent, objective and free of bias and based on evidence. In order to resolve any identified Conflicts of Interest, CME speakers and planners have disclosed all relevant commercial financial relationships received within the past 12 months. Disclosure information has been reviewed to ensure resolution of any identified conflicts.

    Dr. Sevarino has no relevant relationships to disclose.

    All speakers have been advised that any recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in the presentation must conform to the generally accepted standards of experimental design, data collection, and analysis. Speakers must inform learners if their presentation will include discussion of unlabeled/investigational use of commercial products.

    Credit Designation Statement
    The Warren Alpert Medical School of Brown University designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    (Tuesday, September 1, 2015)
    Psychosocial Treatments - Webinar Recorded from July 16, 2012
    Edward V. Nunes, MD
    NYS Psychiatric Institute
    Columbia University College of Physicians and Surgeons
    New York, New York

    Release Date: September 1, 2012 Expiration Date: September 1, 2015

    Educational Objectives
    At the conclusion of this enduring material, participants should be able to:
    • Review the foundation of Motivational Interviewing.
    • Examine empirically supported behavioral treatments for substance dependence.
    • Review the principles of integrating behavioral and medication treatment with examples.
    • Identify specific medication-behavioral combinations.

    Faculty Disclosure
    AAAP and the Brown CME Program aim to provide educational information that is balanced, independent, objective and free of bias and based on evidence. In order to resolve any identified Conflicts of Interest, CME speakers and planners have disclosed all relevant commercial financial relationships received within the past 12 months. Disclosure information has been reviewed to ensure resolution of any identified conflicts. This activity's planning committee has determined that the speaker's disclosure information below poses no bias or conflict to this presentation.

    Dr. Nunes is PI on a NIDA-funded R01 that receives free medication (long-acting injectable naltrexone) from Alkermes, Inc.

    All speakers have been advised that any recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in the presentation must conform to the generally accepted standards of experimental design, data collection, and analysis. Speakers must inform learners if their presentation will include discussion of unlabeled/investigational use of commercial products.

    Credit Designation Statement
    The Warren Alpert Medical School of Brown University designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    (Tuesday, September 1, 2015)
    Psychostimulant Use Disorders - Webinar Recorded from July 23, 2012
    Steven Batki, MD
    University of California San Francisco
    San Francisco, California

    Release Date: September 1, 2012 Expiration Date: September 1, 2015

    Educational Objectives
    At the conclusion of this enduring material, participants should be able to:
    • Review background & history of psychostimulant disorders.
    • Discuss the epidemiology and genetic involvement in psychostimulant disorders.
    • Determine the diagnostic factors involved in this disorder.
    • Discuss pharmacology.
    • Determine the clinical effects and pathophysiology/adverse effects and treatment

    Faculty Disclosure
    AAAP and the Brown CME Program aim to provide educational information that is balanced, independent, objective and free of bias and based on evidence. In order to resolve any identified Conflicts of Interest, CME speakers and planners have disclosed all relevant commercial financial relationships received within the past 12 months. Disclosure information has been reviewed to ensure resolution of any identified conflicts. This activity's planning committee has determined that the speaker's disclosure information below poses no bias or conflict to this presentation.

    Dr. Batki is a grant recipient of an investigation award from Pfizer, Inc. for tobacco cessation and is on the Pfizer, Inc. Advisory Committee for tobacco cessation.

    All speakers have been advised that any recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in the presentation must conform to the generally accepted standards of experimental design, data collection, and analysis. Speakers must inform learners if their presentation will include discussion of unlabeled/investigational use of commercial products.

    Credit Designation Statement
    The Warren Alpert Medical School of Brown University designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    (Tuesday, September 1, 2015)
    Alcohol Use Disorders- Webinar Recorded from July 30, 2012
    Bryon Adinoff, MD
    University of Texas Southwestern Medical Center
    VA North Texas Health Care System
    Dallas, Texas

    Release Date: September 1, 2012 Expiration Date: September 1, 2015

    Educational Objectives
    At the conclusion of this enduring material, participants should be able to:
    • Review the history and epidemiology of alcohol disorders.
    • Determine the risk factors with alcohol disorders.
    • Review pharmacology.
    • Determine consequences and treatment approach.

    Faculty Disclosure
    AAAP and the Brown CME Program aim to provide educational information that is balanced, independent, objective and free of bias and based on evidence. In order to resolve any identified Conflicts of Interest, CME speakers and planners have disclosed all relevant commercial financial relationships received within the past 12 months. Disclosure information has been reviewed to ensure resolution of any identified conflicts. This activity's planning committee has determined that the speaker's disclosure information below poses no bias or conflict to this presentation.
    Dr. Adinoff has done consultation with law firms on medical malpractice, including: Shook, Hardy & Bacon LLP representing tobacco companies.

    All speakers have been advised that any recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in the presentation must conform to the generally accepted standards of experimental design, data collection, and analysis. Speakers must inform learners if their presentation will include discussion of unlabeled/investigational use of commercial products.

    Credit Designation Statement
    The Warren Alpert Medical School of Brown University designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


    (Tuesday, September 1, 2015)
    Tobacco Use Disorders and Smoking Cessation - Webinar Recorded from August 6, 2012
    Judith Prochaska, PhD, MPH
    Associate Professor in Residence, Department of Psychiatry University of California
    San Francisco, California

    Release Date: September 1, 2012 Expiration Date: September 1, 2015

    Educational Objectives
    At the conclusion of this enduring material, participants should be able to:
    • Review the epidemiology of tobacco use.
    • Discuss nicotine addiction.
    • Review the pharmacotherapy of nicotine addiction.
    • Discuss cessation counseling.
     
    Faculty Disclosure
    AAAP and the Brown CME Program aim to provide educational information that is balanced, independent, objective and free of bias and based on evidence. In order to resolve any identified Conflicts of Interest, CME speakers and planners have disclosed all relevant commercial financial relationships received within the past 12 months. Disclosure information has been reviewed to ensure resolution of any identified conflicts. This activity's planning committee has determined that the speaker's disclosure information below poses no bias or conflict to this presentation.

    Dr. Prochaska has received a Pfizer Investigator Initiated Research Award.

    All speakers have been advised that any recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in the presentation must conform to the generally accepted standards of experimental design, data collection, and analysis. Speakers must inform learners if their presentation will include discussion of unlabeled/investigational use of commercial products.

    Credit Designation Statement
    The Warren Alpert Medical School of Brown University designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    (Tuesday, September 1, 2015)
    Club Drugs/Marijuana - Webinar Recorded from August 13, 2012
    Petros Levounis, MD
    The Addiction Institute of New York
    St. Luke's and Roosevelt Hospitals
    New York, New York

    Release Date: September 1, 2012 Expiration Date: September 1, 2015

    Educational Objectives
    At the conclusion of this enduring material, participants should be able to:
    • Discuss the basic elements of club drugs and marijuana.
    • Review the epidemiology and pharmacology of Ecstasy, Ketamine, GHB, Marijuana and Bath Salts 

    Faculty Disclosure
    AAAP and the Brown CME Program aim to provide educational information that is balanced, independent, objective and free of bias and based on evidence. In order to resolve any identified Conflicts of Interest, CME speakers and planners have disclosed all relevant commercial financial relationships received within the past 12 months. Disclosure information has been reviewed to ensure resolution of any identified conflicts.

    Dr. Levounis has no relevant relationships to disclose.

    All speakers have been advised that any recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in the presentation must conform to the generally accepted standards of experimental design, data collection, and analysis. Speakers must inform learners if their presentation will include discussion of unlabeled/investigational use of commercial products.

    Credit Designation Statement
    The Warren Alpert Medical School of Brown University designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    (Tuesday, September 1, 2015)
    Opioid Use Disorders - Webinar Recorded from August 20, 2012
    Elinore McCance-Katz, MD, PhD
    Professor of Psychiatry University of California
    San Francisco, California

    Release Date: September 1, 2012 Expiration Date: September 1, 2015

    Educational Objectives
    At the conclusion of this enduring material, participants should be able to:
    • Describe the epidemiology and neurobiology of opioid use disorders
    • Define the types of opioids and their effects
    • Describe the pharmacology and treatment modalities of opioids
    • Identify issues in pregnancy and other special groups

    Faculty Disclosure
    AAAP and the Brown CME Program aim to provide educational information that is balanced, independent, objective and free of bias and based on evidence. In order to resolve any identified Conflicts of Interest, CME speakers and planners have disclosed all relevant commercial financial relationships received within the past 12 months. Disclosure information has been reviewed to ensure resolution of any identified conflicts.

    Dr. McCance-Katz has no relevant financial relationships to disclose.

    All speakers have been advised that any recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in the presentation must conform to the generally accepted standards of experimental design, data collection, and analysis. Speakers must inform learners if their presentation will include discussion of unlabeled/investigational use of commercial products.

    Credit Designation Statement
    The Warren Alpert Medical School of Brown University designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Top